Патология костно-мышечной системы: фокус на саркопению и остеосаркопению
Аннотация
В течение последних 40 лет уделяется большое внимание состоянию мышечной ткани и ее функции у пожилых людей, что связано с повышенным риском падений и переломов в данной популяции лиц. В 1989 г. был предложен термин «саркопения» для обозначения снижения массы и силы скелетных мышц в процессе старения, а в 2010 г. Европейская рабочая группа по изучению саркопении представила определение и диагностические критерии данного состояния. В 2016 г. саркопении был присвоен код М62.84 для ее обозначения как заболевания мышц в МКБ-10. Статья знакомит читателей с классификацией, факторами риска и методами диагностики данного заболевания, представлены обновленные критерии его диагностики, а также дано определение понятия «остеосаркопения». Описаны возможные методы профилактики и лечения для улучшения качества жизни больных, страдающих саркопенией и остеосаркопенией.
Ключевые слова
Об авторах
Н. В. Торопцова
Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт ревматологии имени В.А. Насоновой
Россия
Россия
Торопцова Наталья Владимировна - доктор медицинских наук, врач-ревматолог высшей квалификационной категории, заведующий лабораторией остеопороза отдела метаболических заболеваний костей и суставов.
115522, Москва, Каширское шоссе, д. 34а; тел.: +7 (495) 109-29-10
А. Ю. Феклистов
Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт ревматологии имени В.А. Насоновой
Россия
Россия
Феклистов Алексей Юрьевич - младший научный сотрудник, врач-ревматолог лаборатории остеопороза отдела метаболических заболеваний костей и суставов.
115522, Москва, Каширское шоссе, д. 34а; тел.: +7 (495) 109-29-10
Список литературы
1. Rosenberg I. Summary comments. Am. J. Clin. Nutr. 1989;50:1231-1233.
2. Schaap L.A., van Schoor N.M., Lips P. et al. Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study Amsterdam. J Gerontol A Biol Sci Med Sci. 2018;73:1199-204.
3. Malmstrom T.K., Miller D.K., Simonsick E.M. et al. SARC-F: asymptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7:28-36.
4. Bahat G., Ilhan B. Sarcopenia and the cardio-metabolic syndrome: a narrative review. Eur Geriatr Med. 2016;6:220-23.
5. Bone A.E., Hepgul N., Kon S. et al. Sarcopenia and frailty in chronic respiratory disease. Chron Respir Dis. 2017;14:85-99.
6. Chang K.V., Hsu T.H., Wu W.T. et al. Association between sarcopenia and cognitive impairment: a systematic review and metaanalysis. J Am Med Dir Assoc. 2016;17:1164.e7-64.e15.
7. Dos Santos L., Cyrino E.S., Antunes M. et al. Sarcopenia and physical independence in older adults: the independent and synergic role of muscle mass and muscle function. J Cachexia Sarcopenia Muscle. 2017;8:245-50.
8. Steffl M., Bohannon R.W., Sontakova L. et al. Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging. 2017;12:835-45.
9. De Buyser S.L., Petrovic M., Taes YE. et al. Validation of the FNIH sarcopenia criteria and SOF frailty index as predictors of long-term mortality in ambulatory older men. Age Ageing. 2016;45:602-8.
10. Antunes A.C., Araujo D.A., Verissimo M.T. et al. Sarcopenia and hospitalisation costs in older adults: a cross-sectional study. Nutr Diet. 2017;74:46-50.
11. Steffl M., Sima J., Shiells K. et al. The increase in health care costs associated with muscle weakness in older people without long-term illnesses in the Czech Republic: results from the Survey of Health, Ageing and Retirement in Europe (SHARE). Clin IntervAging. 2017;12:2003-07.
12. Cruz-Jentoft AJ., Baeyens J.P., Bauer J.M. et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older people. Age Ageing. 2010;39(4):412-423. doi: 10.1093/age-ing/afq034.
13. Anker S.D., Morley J.E., von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle. 2016;7(5):512-514. doi.org/10.1002/jcsm.12147.
14. Shafiee G., Keshtkar A., Soltani A. et al. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord. 2017;16;16:21. doi: 10.11 86/s40200-017-0302-x.eCollection 2017.
15. Landi F., Calvani R., Tosato M. et al. Impact of physical function impairment and multimorbidity on mortality among communityliving older persons with sarcopaenia: results from the ilSIRENTE prospective cohort study. BMJ Open. 2016;6:e008281. doi:10.1136/bmjopen-2015-008281.
16. Cruz-Jentoft AJ., Bahat G., Bauer J. et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169.
17. Beaudart C., McCloskey E., Bruyere O. et al. Sarcopenia in daily practice: assessment and management. BMC Geriatr. 2016;16:170. doi: 10.1186/s12877-016-0349-4.
18. Cesari M., Kritchevsky S.B., Newman A.B. et al. Added value of physical performance measures in predicting adverse healthrelated events: results from the health, aging and body composition study. J Am Geriatr Soc. 2009;57:251-9. doi.org/10.1111/j.1532-5415.2008.02126.x.
19. Jones CJ., Rikli R.E., Beam W.C. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport. 1999;70:113-9.
20. Pavasini R., Guralnik J., Brown J.C. et al. Short physical performance battery and all-cause mortality: systematic review and meta-analysis. BMC Med. 2016;14:215. doi.org/10.1186/s12916-016-0763-7.
21. Vestergaard S., Patel K.V., Bandinelli S. et al. Characteristics of 400-meter walk test performance and subsequent mortality in older adults. Rejuvenation Res. 2009;12:177-84.
22. Landi F., Onder G., Russo A. et al. Calf circumference, frailty and physical performance among older adults living in the community. Clin Nutr. 2014;33:539-44.
23. Binkley N., Buehring B. Beyond FRAX: It’s time to consider ‘sarco-osteopenia’. J Clin Densitom. 2009;12(4):413-16.
24. Huo Y.R., Suriyaarachchi P., Gomez F. et al. Phenotype of osteosarcopenia in older individuals with a history of falling. J Am Med Dir Assoc. 2015;16(4):290-95.
25. Demontiero O., Boersma D., Suriyaarachchi P. et al. Clinical outcomes of impaired muscle and bone interactions. Clin Rev Bone Miner Metab. 2014;12:86-92. doi: 10.1007/s12018-014-9164-7.
26. Mera P, Laue K., Ferron M. et al. Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab. 2016;23(6):1078-1092. doi: 10.1016/j.cmet.2016.05.004.
27. Tagliaferri C., Wittrant Y., Davicco MJ. et al. Muscle and bone, two interconnected tissues. Ageing Res Rev. 2015;21:55-57. doi: 10.1016/j.arr.2015.03.002.
28. Hassan E.B., Duque G. Osteosarcopenia: A new geriatric syndrome. Aust Fam Physician. 2017 Nov;46(11):849-853.
29. Beaudart C., Dawson A., Shaw C. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos Int. 2017;28:1817-1833. doi 10.1007/s00198-017-3980-9.
30. Hickson M. Conference on ‘Nutrition and age-related muscle loss, sarcopenia and cachexia’ Symposium 3: Nutrition for prevention and interventions for sarcopenia and cachexia Nutritional interventions in sarcopenia: a critical review. Proceedings of the Nutrition Society. 2015;74:378-386. doi:10.1017/S0029665115002049.
31. Bauer J., Biolo G., Cederholm T., Cesari M., Cruz-Jentoft AJ., Morley J.E. et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group. J Am Med Dir Assoc. 2013;14(8):542e59. http//dx.doi.org/10.1016/j.jamda.2013.05.021.
32. Gerdhem P., Ringsberg K.A., Obrant KJ., Akesson K.Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OprA Study of Elderly Women. Osteoporos. Int. 2005;16(11):1425-1431.
33. Nakamura K., Oshiki R., Hatakeyama K. et al. Vitamin D status, postural sway, and the incidence of falls in elderly community-dwelling Japanese women. Arch. Osteoporos. 2006;1:21-27.
34. Udowenko M., Trojian T. Vitamin D: extent of deficiency, effect on muscle function, bone health, performance, and injury prevention. Conn Med. 2010 Sep;74(8):477-80.
35. Jackson C., Gaugris S., Sen S.S., Hosking D. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. QJM. 2007;100(4):185-192.
36. Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H.B., Orav J.E., Stuck A.E., Theiler R., Wong J.B., Egli A., Kiel D.P., Henschkowski J. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009 Oct 1;339:b3692. doi: 10.1136/bmj.b3692.
37. Bunout D., Barrera G., Leiva L. et al. Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects. Exp Gerontol. 2006;41:746-752. doi:10.1016/j.exger.2006.05.001.
38. Binder E.F. Implementing a structured exercice program for frail nursing home residents with dementia: issues and challenge. JAPA. 1996;3(4):383-395. doi:10.1123/japa.3.4.383.
39. Торопцова Н.В., Никитинская О.А. Остеопороз в реальной клинической практике: фокус на альфакальцидол. Фарматека. 2016;19(332):36-41. [Toroptsova N.V., Nikitinskaya O.A. Osteoporosis in real clinical practice: focus on alphacalcidol. Pharmacy [Farmateka]. 2016;19(332):36-41. (In Russ.)]
40. Dukas L., Schacht E., Runge M. Independent from muscle power and balance performance, a creatinine clearance below 65 ml/min is a significant and independent risk factor for falls and fall-related fractures in elderly men and women diagnosed with osteoporosis. Osteoporos. Int. 2010;21(7):1237-1245.
41. Schacht E., Richy F., Reginster J.Y. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J. Musculoskelet. Neuronal. Interact. 2005;5(3):273-284.
42. Shibata T., Shira-Ishi A., Sato T., Masaki T., Sasaki A., Masuda Y., Hishiya A., Ishikura N., Higashi S., Uchida Y., Saito M., Ito M., Ogata E., Watanabe K., Ikeda K. Vitamin D hormone inhibits osteoclastogenesis in vivoby decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res. 2002;17:622-629.
43. Shiraishi A., Higashi S., Okawa H., Ogata E. The effect of 1-(OH)D3 on bone metabolism in par-athyroidectomized rats with continuous PTH infusion. Osteoporos. Int. 1997;7(Suppl.2):35.
44. Richy F., Ethgen O., Bruyere O., Reginster J.-Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a metaanalysis of their effects on bone mineral density and fracture rate. Osteoporos Int. 2004;15:301-310.
45. Bischoff-Ferrari H.A., Borchers M., Gudat F., Dur-muller U., Stahelin H.B., Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res. 2004;19:265-269.
46. Dukas L., Schacht E., Bischoff H.A. Better functional mobility in community dwelling elderly is related to D-hormone serum levels and to a daily calcium intake. J. Nutrition Health and Aging. 2005;9:347-351.
47. Sorensen O.H., Lund B., Saltin B. et al. Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalcif-erol and calcium. Clin Sci 1979;56:157-161.
48. Verhaar HJJ., Samson M.M., Jansen PA.F., de Vreede PL., Manten J.W, Duursma S.A. Muscle strength, functional mobility and vitamin D in older women. Aging Clin Exp Res. 2000;12:455-460.
49. Scharla S.H., Schacht E., Bawey S., Kamilli I., Holle D., Lempert U.G. Pleiotropic effects of alfacalcidol in elderly patients with rheumatoid arthritis. Arthr Rheum. 2003;23:268-274.
50. Dukas L., Bischoff H.A., Lindpaintner L.S., Schacht E., Birkner-Binder D., Damm T.N., Thalmann B., Stahelin H.B. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc. 2004;52:230-236.
51. Dukas L., Schacht E., Mazor Z., Stahelin H.B. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporos. Int. 2005;16:198-203.
52. Dukas L., Schacht E., Runge M., Ringe J.D. Effect of a six-month therapy with alfacalcidol on muscle power and balance and the number of fallers and falls. Arzneimittelforschung. 2010;60(8):519-25. doi: 10.1055/s-0031-1296321.
53. Schacht E., Ringe J.D. Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone mass. Rheumatol Int. 2012 Jan;32(1):207-15. doi: 10.1007/s00296-010-1607-y.
54. Morley J.E. Pharmacologic options for the treatment of sarcopenia. Calcif Tissue Int. 2016;98(4): 319-33. doi: 10.1007/s00223-015-0022-5.
Для цитирования:
Торопцова Н.В., Феклистов А.Ю. Патология костно-мышечной системы: фокус на саркопению и остеосаркопению. Медицинский Совет. 2019;(4):78-86. https://doi.org/10.21518/2079-701X-2019-4-78-86
For citation:
Toroptsova N.V., Feklistov A.Yu. Musculoskeletal system pathology: focus on sarcopenia and osteosarcopenia. Meditsinskiy sovet = Medical Council. 2019;(4):78-86. (In Russ.) https://doi.org/10.21518/2079-701X-2019-4-78-86
Просмотров: 483
Послать статью по эл. почте 
